MentionFox
Home › 5%+ stakes › Manufacturing (industry group 28), latest filing in May 2026
5%+ stakes

Manufacturing (industry group 28), latest filing in May 2026

18 companies with 5%+ holders, every filing linked: Adaptive Biotechnologies Corp, AIM ImmunoTech Inc., Air Products and Chemicals Inc, Akebia Therapeutics Inc, Alkermes Plc, Alnylam Pharmaceuticals Inc and more. Each section is the company's full record from its filings, newest filings first within each section.

18 companies with 5%+ holders on this page (Manufacturing (industry group 28), latest filing in May 2026), each linked to its filing, starting with Adaptive Biotechnologies Corp, AIM ImmunoTech Inc., Air Products and Chemicals Inc. Free check on any of them: https://mentionfox.com/check

On this page

Adaptive Biotechnologies Corp

At 5% or more2
Filings4
Latest filing2026-05-15

Adaptive Biotechnologies Corp has 4 Schedule 13D or 13G filings on record since 2025-07-09. 2 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Viking Global Investors LP18.8%29,993,708SCHEDULE 13G/A, 2026-05-152026-03-31
BlackRock, Inc.7.9%11,992,448SCHEDULE 13G/A, 2026-01-212025-12-31
Rubric Capital Management LP4.12%6,256,847SCHEDULE 13G/A, 2025-07-092025-06-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Viking Global Investors LP029,993,708029,993,708SCHEDULE 13G/A, 2026-05-15
Viking Global Performance LLC022,002,189022,002,189SCHEDULE 13G/A, 2026-05-15
Viking Global Equities II LP0440,0460440,046SCHEDULE 13G/A, 2026-05-15
Viking Global Equities Master Ltd.021,562,143021,562,143SCHEDULE 13G/A, 2026-05-15
Viking Long Fund GP LLC07,991,51907,991,519SCHEDULE 13G/A, 2026-05-15
Viking Long Fund Master Ltd.07,991,51907,991,519SCHEDULE 13G/A, 2026-05-15
Halvorsen Ole Andreas029,993,708029,993,708SCHEDULE 13G/A, 2026-05-15
Shabet Rose Sharon029,993,708029,993,708SCHEDULE 13G/A, 2026-05-15
BlackRock, Inc.11,764,835011,992,4480SCHEDULE 13G/A, 2026-01-21
Rubric Capital Management LP06,256,84706,256,847SCHEDULE 13G/A, 2025-07-09
David Rosen06,256,84706,256,847SCHEDULE 13G/A, 2025-07-09
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Adaptive Biotechnologies Corp by CUSIP 00650F109 and gives its principal executive office as 1165 Eastlake Avenue East, Seattle, WA 98109 (SCHEDULE 13G/A, 2026-05-15).

FiledHolderPercentFiling
2025-07-09Rubric Capital Management LP4.12%SCHEDULE 13G/A
2026-01-21BlackRock, Inc.7.9%SCHEDULE 13G/A
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-05-15Viking Global Investors LP18.8%SCHEDULE 13G/A

AIM ImmunoTech Inc.

At 5% or more1
Filings2
Latest filing2026-05-27

AIM ImmunoTech Inc. has 2 Schedule 13D or 13G filings on record since 2026-05-12. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Orca Capital AG9.9%1,793,999SCHEDULE 13G, 2026-05-122026-05-07
Mitchell P. Kopin0%0SCHEDULE 13G, 2026-05-272026-05-20
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Orca Capital AG1,793,99901,793,9990SCHEDULE 13G, 2026-05-12
Mitchell P. Kopin0000SCHEDULE 13G, 2026-05-27
Daniel B. Asher0000SCHEDULE 13G, 2026-05-27
Intracoastal Capital LLC0000SCHEDULE 13G, 2026-05-27

The latest filing identifies AIM ImmunoTech Inc. by CUSIP 00901B303 and gives its principal executive office as 2117 SW Highway 484, Ocala, FL 34473 (SCHEDULE 13G, 2026-05-27).

FiledHolderPercentFiling
2026-05-12Orca Capital AG9.9%SCHEDULE 13G
2026-05-27Mitchell P. Kopin0%SCHEDULE 13G

Air Products and Chemicals Inc

At 5% or more2
Filings8
Latest filing2026-10-30

Air Products and Chemicals Inc has 8 Schedule 13D or 13G filings on record since 2025-08-13. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Capital Management7.51%16,740,723SCHEDULE 13G, 2026-04-292026-03-31
Vanguard Portfolio Management5.36%11,949,109SCHEDULE 13G, 2026-10-302026-09-30
Capital Research Global Investors4.7%10,412,267SCHEDULE 13G/A, 2026-05-142026-03-31
Capital International Investors4.6%10,168,256SCHEDULE 13G/A, 2026-05-142026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management2,273,407016,740,7230SCHEDULE 13G, 2026-04-29
Vanguard Portfolio Management26,401011,949,1090SCHEDULE 13G, 2026-10-30
Capital Research Global Investors10,407,997010,412,2670SCHEDULE 13G/A, 2026-05-14
Capital International Investors9,863,191010,168,2560SCHEDULE 13G/A, 2026-05-14
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Air Products and Chemicals Inc by CUSIP 009158106 and gives its principal executive office as 1940 Air Products Blvd, Allentown, PA 18106 (SCHEDULE 13G, 2026-10-30).

FiledHolderPercentFiling
2025-08-13Capital Research Global Investors5.2%SCHEDULE 13G/A
2026-01-07The Vanguard Group10.02%SCHEDULE 13G/A
2026-02-13Capital International Investors5.8%SCHEDULE 13G
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Capital Management7.51%SCHEDULE 13G
2026-05-14Capital Research Global Investors4.7%SCHEDULE 13G/A
2026-05-14Capital International Investors4.6%SCHEDULE 13G/A
2026-10-30Vanguard Portfolio Management5.36%SCHEDULE 13G

Akebia Therapeutics Inc

At 5% or more1
Filings4
Latest filing2026-05-12

Akebia Therapeutics Inc has 4 Schedule 13D or 13G filings on record since 2026-01-21. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.7.2%19,219,819SCHEDULE 13G/A, 2026-01-212025-12-31
State Street Corporation4.3%11,614,006SCHEDULE 13G, 2026-05-122026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.18,844,036019,219,8190SCHEDULE 13G/A, 2026-01-21
State Street Corporation011,269,922011,614,006SCHEDULE 13G, 2026-05-12
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Akebia Therapeutics Inc by CUSIP 00972D105 and gives its principal executive office as 245 FIRST STREET SUITE 1100, CAMBRIDGE, MA 02142 (SCHEDULE 13G, 2026-05-12).

FiledHolderPercentFiling
2026-01-21BlackRock, Inc.7.2%SCHEDULE 13G/A
2026-02-09State Street Corporation5.2%SCHEDULE 13G
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-05-12State Street Corporation4.3%SCHEDULE 13G
DateRecordFigureOur pageSource
October 14, 2026Leadership change: Nicholas Grund departs, Chief Commercial Officer—Leadership changesSource

Alkermes Plc

At 5% or more4
Filings7
Latest filing2026-05-15

Alkermes Plc has 7 Schedule 13D or 13G filings on record since 2025-08-14. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Baker Bros. Advisors LP6.1%10,012,267SCHEDULE 13G, 2026-02-172025-12-31
Vanguard Portfolio Management5.8%9,647,056SCHEDULE 13G, 2026-04-282026-03-31
Vanguard Capital Management5.21%8,676,888SCHEDULE 13G, 2026-04-282026-03-31
State Street Corporation5.2%8,540,351SCHEDULE 13G, 2025-11-102025-09-30
T. Rowe Price Associates, Inc.2.8%4,664,563SCHEDULE 13G/A, 2026-05-152026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Portfolio Management135,94409,647,0560SCHEDULE 13G, 2026-04-28
Vanguard Capital Management1,249,49108,676,8880SCHEDULE 13G, 2026-04-28
T. Rowe Price Associates, Inc.4,650,68704,664,5630SCHEDULE 13G/A, 2026-05-15
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Alkermes Plc by CUSIP G01767105 and gives its principal executive office as CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN (SCHEDULE 13G/A, 2026-05-15).

FiledHolderPercentFiling
2025-08-14T. Rowe Price Associates, Inc.6.1%SCHEDULE 13G/A
2025-11-10State Street Corporation5.2%SCHEDULE 13G
2026-02-17Baker Bros. Advisors LP6.1%SCHEDULE 13G
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-28Vanguard Capital Management5.21%SCHEDULE 13G
2026-04-28Vanguard Portfolio Management5.8%SCHEDULE 13G
2026-05-15T. Rowe Price Associates, Inc.2.8%SCHEDULE 13G/A
DateRecordFigureOur pageSource
September 16, 2026Leadership change: Anne C. Whitaker appointed, Director—Leadership changesSource
August 3, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource
February 11, 2026Acquired Avadel$1.50BAcquisitionSource

Alnylam Pharmaceuticals Inc

At 5% or more5
Filings8
Latest filing2026-11-05

Alnylam Pharmaceuticals Inc has 8 Schedule 13D or 13G filings on record since 2025-11-05. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Fmr LLC9.5%12,675,053SCHEDULE 13G/A, 2026-11-052026-09-30
Capital World Investors8.2%10,916,799SCHEDULE 13G/A, 2026-05-142026-03-31
Capital Research Global Investors7.1%9,471,181SCHEDULE 13G/A, 2026-05-142026-03-31
Vanguard Capital Management5.35%7,104,536SCHEDULE 13G, 2026-04-292026-03-31
Vanguard Portfolio Management5.03%6,732,082SCHEDULE 13G, 2026-10-302026-09-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Fmr LLC12,035,986012,675,0530SCHEDULE 13G/A, 2026-11-05
Abigail P. Johnson0012,675,0530SCHEDULE 13G/A, 2026-11-05
Capital World Investors10,871,837010,916,7990SCHEDULE 13G/A, 2026-05-14
Capital Research Global Investors9,455,76509,471,1810SCHEDULE 13G/A, 2026-05-14
Vanguard Capital Management1,157,83007,104,5360SCHEDULE 13G, 2026-04-29
Vanguard Portfolio Management34,16206,732,0820SCHEDULE 13G, 2026-10-30

The latest filing identifies Alnylam Pharmaceuticals Inc by CUSIP 02043Q107 and gives its principal executive office as 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (SCHEDULE 13G/A, 2026-11-05).

FiledHolderPercentFiling
2025-11-05Fmr LLC12.8%SCHEDULE 13G/A
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Capital Management5.35%SCHEDULE 13G
2026-05-06Fmr LLC11%SCHEDULE 13G/A
2026-05-14Capital Research Global Investors7.1%SCHEDULE 13G/A
2026-05-14Capital World Investors8.2%SCHEDULE 13G/A
2026-10-30Vanguard Portfolio Management5.03%SCHEDULE 13G
2026-11-05Fmr LLC9.5%SCHEDULE 13G/A
DateRecordFigureOur pageSource
November 5, 2026Leadership change: Tolga Tanguler departs, Chief Commercialization Officer—Leadership changesSource
May 27, 2026Leadership change: Benjamin F. Cravatt appointed—Leadership changesSource

Amgen Inc.

At 5% or more2
Filings4
Latest filing2026-05-14

Amgen Inc. has 4 Schedule 13D or 13G filings on record since 2025-09-08. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Capital Management7.51%40,510,484SCHEDULE 13G, 2026-04-292026-03-31
Capital World Investors5.5%29,596,119SCHEDULE 13G, 2026-05-142026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management5,496,252040,510,4840SCHEDULE 13G, 2026-04-29
Capital World Investors29,296,381029,596,1190SCHEDULE 13G, 2026-05-14
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Amgen Inc. by CUSIP 031162100 and gives its principal executive office as One Amgen Center Drive, Thousand Oaks (SCHEDULE 13G, 2026-05-14).

FiledHolderPercentFiling
2025-09-08The Vanguard Group10%SCHEDULE 13G/A
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Capital Management7.51%SCHEDULE 13G
2026-05-14Capital World Investors5.5%SCHEDULE 13G
DateRecordFigureOur pageSource
October 27, 2026Leadership change: David W. Gibbs appointed, Director—Leadership changesSource
May 19, 2026Leadership change: Peter H. Griffith departs, Chief Financial Officer—Leadership changesSource
April 22, 2026Leadership change: David M. Reese departs, Executive Vice President—Leadership changesSource

Belite Bio, Inc

At 5% or more1
Filings3
Latest filing2026-05-14

Belite Bio, Inc has 3 Schedule 13D or 13G filings on record since 2025-12-10. 1 holder's latest filing reports 5% or more of ordinary shares, par value us$0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Darwin Global Management, Ltd.8.1%3,027,704SCHEDULE 13G/A, 2026-02-172025-12-31
Yu-Hsin Lin3.1%1,253,935SCHEDULE 13G/A, 2026-05-142026-03-31
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Darwin Global Management, Ltd.03,027,70403,027,704SCHEDULE 13G/A, 2026-02-17
Trehan Abhishek03,027,70403,027,704SCHEDULE 13G/A, 2026-02-17
Darwin Global Master Fund, Ltd.02,928,57502,928,575SCHEDULE 13G/A, 2026-02-17
Yu-Hsin Lin1,253,93501,253,9350SCHEDULE 13G/A, 2026-05-14

The latest filing identifies Belite Bio, Inc by CUSIP 07782B104 and gives its principal executive office as 12750 High Bluff Drive, Suite 475, San Diego, CA 92130 (SCHEDULE 13G/A, 2026-05-14).

FiledHolderPercentFiling
2025-12-10Darwin Global Management, Ltd.7%SCHEDULE 13G
2026-02-17Darwin Global Management, Ltd.8.1%SCHEDULE 13G/A
2026-05-14Yu-Hsin Lin3.1%SCHEDULE 13G/A

Cibus Inc

At 5% or more1
Filings3
Latest filing2026-05-06

Cibus Inc has 3 Schedule 13D or 13G filings on record since 2025-08-14. 1 holder's latest filing reports 5% or more of class a common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Fmr LLC15%11,425,929SCHEDULE 13G/A, 2026-05-062026-03-31
Armistice Capital, LLC4.99%2,540,536SCHEDULE 13G/A, 2025-08-142025-06-30
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Fmr LLC11,425,929011,425,9290SCHEDULE 13G/A, 2026-05-06
Abigail P. Johnson0011,425,9290SCHEDULE 13G/A, 2026-05-06
Armistice Capital, LLC02,540,53602,540,536SCHEDULE 13G/A, 2025-08-14
Steven Boyd02,540,53602,540,536SCHEDULE 13G/A, 2025-08-14

The latest filing identifies Cibus Inc by CUSIP 17166A101 and gives its principal executive office as 6455 NANCY RIDGE DRIVE, San Diego, CA 92121 (SCHEDULE 13G/A, 2026-05-06).

FiledHolderPercentFiling
2025-08-14Armistice Capital, LLC4.99%SCHEDULE 13G/A
2026-02-05Fmr LLC13.9%SCHEDULE 13G/A
2026-05-06Fmr LLC15%SCHEDULE 13G/A
DateRecordFigureOur pageSource
June 9, 2026Leadership change: Craig Wichner appointed, Chief Executive Officer, and 2 more—Leadership changesSource
April 10, 2026Leadership change: Thomas Urban appointed, Director—Leadership changesSource

Ingevity Corporation

At 5% or more2
Filings5
Latest filing2026-05-15

Ingevity Corporation has 5 Schedule 13D or 13G filings on record since 2025-10-24. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Portfolio Management6.27%2,209,879SCHEDULE 13G, 2026-04-292026-03-31
Vanguard Capital Management5.26%1,853,415SCHEDULE 13G, 2026-04-302026-03-31
Wellington Management Group LLP4.2%1,494,292SCHEDULE 13G/A, 2026-05-152026-03-31
Victory Capital Management, Inc.2.15%782,930SCHEDULE 13G/A, 2025-10-242025-09-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Portfolio Management33,14802,209,8790SCHEDULE 13G, 2026-04-29
Vanguard Capital Management271,54401,853,4150SCHEDULE 13G, 2026-04-30
Wellington Management Group LLP01,251,09601,494,292SCHEDULE 13G/A, 2026-05-15
Wellington Group Holdings LLP01,251,09601,494,292SCHEDULE 13G/A, 2026-05-15
Wellington Investment Advisors Holdings LLP01,251,09601,494,292SCHEDULE 13G/A, 2026-05-15
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Ingevity Corporation by CUSIP 45688C107 and gives its principal executive office as 4920 O'Hear Avenue, Suite 400, North Charleston (SCHEDULE 13G/A, 2026-05-15).

FiledHolderPercentFiling
2025-10-24Victory Capital Management, Inc.2.15%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Portfolio Management6.27%SCHEDULE 13G
2026-04-30Vanguard Capital Management5.26%SCHEDULE 13G
2026-05-15Wellington Management Group LLP4.2%SCHEDULE 13G/A
DateRecordFigureOur pageSource
June 24, 2026Leadership change: Ryan Cotterman appointed, Chief Accounting Officer—Leadership changesSource

Ionis Pharmaceuticals Inc

At 5% or more2
Filings8
Latest filing2026-05-15

Ionis Pharmaceuticals Inc has 8 Schedule 13D or 13G filings on record since 2025-08-12. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Capital World Investors12.8%21,186,369SCHEDULE 13G/A, 2026-05-142026-03-31
Vanguard Capital Management5.05%8,344,732SCHEDULE 13G, 2026-04-302026-03-31
Wellington Management Group LLP4.3%6,879,873SCHEDULE 13G/A, 2025-08-122025-06-30
T. Rowe Price Investment Management, Inc.3.7%6,159,027SCHEDULE 13G/A, 2026-05-152026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Capital World Investors21,186,369021,186,3690SCHEDULE 13G/A, 2026-05-14
Vanguard Capital Management1,226,40208,344,7320SCHEDULE 13G, 2026-04-30
T. Rowe Price Investment Management, Inc.6,140,82006,159,0270SCHEDULE 13G/A, 2026-05-15
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Ionis Pharmaceuticals Inc by CUSIP 462222100 and gives its principal executive office as 2855 GAZELLE COURT, CARLSBAD, CA 92010 (SCHEDULE 13G/A, 2026-05-15).

FiledHolderPercentFiling
2025-08-12Wellington Management Group LLP4.3%SCHEDULE 13G/A
2025-11-14T. Rowe Price Investment Management, Inc.8.3%SCHEDULE 13G/A
2026-01-07Capital World Investors11.1%SCHEDULE 13G/A
2026-02-17T. Rowe Price Investment Management, Inc.5.6%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-30Vanguard Capital Management5.05%SCHEDULE 13G
2026-05-14Capital World Investors12.8%SCHEDULE 13G/A
2026-05-15T. Rowe Price Investment Management, Inc.3.7%SCHEDULE 13G/A
DateRecordFigureOur pageSource
June 8, 2026Leadership change: Ludwig N. Hantson appointed—Leadership changesSource

Johnson & Johnson

At 5% or more1
Filings3
Latest filing2026-05-01

Johnson & Johnson has 3 Schedule 13D or 13G filings on record since 2026-02-05. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Capital Management7.49%180,631,228SCHEDULE 13G, 2026-05-012026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management24,025,8580180,631,2280SCHEDULE 13G, 2026-05-01
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Johnson & Johnson by CUSIP 478160104 and gives its principal executive office as 1 Johnson & Johnson Plaza, New Brunswick, NJ 08933 (SCHEDULE 13G, 2026-05-01).

FiledHolderPercentFiling
2026-02-05The Vanguard Group10.1%SCHEDULE 13G/A
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-05-01Vanguard Capital Management7.49%SCHEDULE 13G
DateRecordFigureOur pageSource
August 4, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource

Metavia Inc.

At 5% or more1
Filings2
Latest filing2026-05-15

Metavia Inc. has 2 Schedule 13D or 13G filings on record since 2025-08-14. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Alyeska Investment Group, L.P.9.99%508,585SCHEDULE 13G, 2026-05-152026-03-31
Armistice Capital, LLC4.99%1,270,887SCHEDULE 13G/A, 2025-08-142025-06-30
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Alyeska Investment Group, L.P.0508,5850508,585SCHEDULE 13G, 2026-05-15
Alyeska Fund GP, LLC0508,5850508,585SCHEDULE 13G, 2026-05-15
Anand Parekh0508,5850508,585SCHEDULE 13G, 2026-05-15
Armistice Capital, LLC01,270,88701,270,887SCHEDULE 13G/A, 2025-08-14
Steven Boyd01,270,88701,270,887SCHEDULE 13G/A, 2025-08-14

The latest filing identifies Metavia Inc. by CUSIP 64132R503 and gives its principal executive office as 545 Concord Avenue, Suite 210, Cambridge, MA 02138 (SCHEDULE 13G, 2026-05-15).

FiledHolderPercentFiling
2025-08-14Armistice Capital, LLC4.99%SCHEDULE 13G/A
2026-05-15Alyeska Investment Group, L.P.9.99%SCHEDULE 13G
DateRecordFigureOur pageSource
May 15, 2025Form D, private offering$10M soldForm D pageSource

Pfizer Inc

At 5% or more1
Filings2
Latest filing2026-05-01

Pfizer Inc has 2 Schedule 13D or 13G filings on record since 2026-03-27. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Capital Management7.51%427,444,872SCHEDULE 13G, 2026-05-012026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management58,014,8600427,444,8720SCHEDULE 13G, 2026-05-01
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Pfizer Inc by CUSIP 717081103 and gives its principal executive office as 66 Hudson Blvd East, New York, NY 10001 (SCHEDULE 13G, 2026-05-01).

FiledHolderPercentFiling
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-05-01Vanguard Capital Management7.51%SCHEDULE 13G
DateRecordFigureOur pageSource
November 3, 2026Leadership change: Cecile Guegan appointed, Chief Financial Officer—Leadership changesSource
June 18, 2026Leadership change: Dave Denton departs, Chief Financial Officer, and 1 more—Leadership changesSource

Schrodinger, Inc.

At 5% or more3
Filings7
Latest filing2026-05-15

Schrodinger, Inc. has 7 Schedule 13D or 13G filings on record since 2025-07-18. 3 holders' latest filing reports 5% or more of common stock, $0.01 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.12.7%8,164,484SCHEDULE 13G/A, 2025-07-182025-06-30
Rubric Capital Management LP9.28%6,000,000SCHEDULE 13G/A, 2026-05-152026-03-31
Vanguard Portfolio Management6.04%3,911,087SCHEDULE 13G, 2026-04-292026-03-31
Sumitomo Mitsui Trust Group, Inc.4.9%3,190,837SCHEDULE 13G/A, 2026-04-302026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Rubric Capital Management LP06,000,00006,000,000SCHEDULE 13G/A, 2026-05-15
David Rosen06,000,00006,000,000SCHEDULE 13G/A, 2026-05-15
Vanguard Portfolio Management48,89003,911,0870SCHEDULE 13G, 2026-04-29
Sumitomo Mitsui Trust Group, Inc.03,190,83703,190,837SCHEDULE 13G/A, 2026-04-30
Amova Asset Management Co., Ltd.03,190,83703,190,837SCHEDULE 13G/A, 2026-04-30
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Schrodinger, Inc. by CUSIP 80810D103 and gives its principal executive office as 1540 Broadway, 24th Floor, New York, NY 10036 (SCHEDULE 13G/A, 2026-05-15).

FiledHolderPercentFiling
2025-07-18BlackRock, Inc.12.7%SCHEDULE 13G/A
2025-10-27Sumitomo Mitsui Trust Group, Inc.7.1%SCHEDULE 13G/A
2026-02-13Rubric Capital Management LP6.47%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Portfolio Management6.04%SCHEDULE 13G
2026-04-30Sumitomo Mitsui Trust Group, Inc.4.9%SCHEDULE 13G/A
2026-05-15Rubric Capital Management LP9.28%SCHEDULE 13G/A
DateRecordFigureOur pageSource
May 20, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource

Tronox Holdings plc

At 5% or more2
Filings4
Latest filing2026-05-15

Tronox Holdings plc has 4 Schedule 13D or 13G filings on record since 2025-10-09. 2 holders' latest filing reports 5% or more of common shares. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Van Eck Associates Corp5.68%9,053,511SCHEDULE 13G, 2026-05-152026-03-31
Dimensional Fund Advisors LP5%7,865,045SCHEDULE 13G/A, 2025-10-092025-09-30
The Vanguard Group4.86%7,707,036SCHEDULE 13G/A, 2026-01-302025-12-31
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Van Eck Associates Corp9,053,51109,053,5110SCHEDULE 13G, 2026-05-15
Dimensional Fund Advisors LP7,716,73107,865,0450SCHEDULE 13G/A, 2025-10-09
The Vanguard Group01,100,39007,707,036SCHEDULE 13G/A, 2026-01-30

The latest filing identifies Tronox Holdings plc by CUSIP G9087Q102 and gives its principal executive office as 263 TRESSER BLVD., SUITE 1100, STAMFORD, CT 06901 (SCHEDULE 13G, 2026-05-15).

FiledHolderPercentFiling
2025-10-09Dimensional Fund Advisors LP5%SCHEDULE 13G/A
2025-10-31The Vanguard Group6.22%SCHEDULE 13G/A
2026-01-30The Vanguard Group4.86%SCHEDULE 13G/A
2026-05-15Van Eck Associates Corp5.68%SCHEDULE 13G
DateRecordFigureOur pageSource
October 28, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource
July 29, 2026Leadership change: Keith Schwarz appointed, Director—Leadership changesSource

Vertex Pharmaceuticals Inc.

At 5% or more3
Filings5
Latest filing2026-05-14

Vertex Pharmaceuticals Inc. has 5 Schedule 13D or 13G filings on record since 2026-02-12. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Capital World Investors10.1%25,695,015SCHEDULE 13G/A, 2026-05-142026-03-31
Capital Research Global Investors8.3%21,139,169SCHEDULE 13G/A, 2026-05-142026-03-31
Vanguard Capital Management7.49%19,036,076SCHEDULE 13G, 2026-04-302026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Capital World Investors25,556,582025,695,0150SCHEDULE 13G/A, 2026-05-14
Capital Research Global Investors21,113,307021,139,1690SCHEDULE 13G/A, 2026-05-14
Vanguard Capital Management2,523,266019,036,0760SCHEDULE 13G, 2026-04-30
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Vertex Pharmaceuticals Inc. by CUSIP 92532F100 and gives its principal executive office as 50 Northern Avenue, Boston (SCHEDULE 13G/A, 2026-05-14).

FiledHolderPercentFiling
2026-02-12Capital Research Global Investors6.8%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-30Vanguard Capital Management7.49%SCHEDULE 13G
2026-05-14Capital Research Global Investors8.3%SCHEDULE 13G/A
2026-05-14Capital World Investors10.1%SCHEDULE 13G/A
DateRecordFigureOur pageSource
October 20, 2026Leadership change: Daniel Brennan appointed, Director—Leadership changesSource
September 1, 2026Leadership change: Jonathan Poole appointed, Chief Financial Officer—Leadership changesSource
April 29, 2026Leadership change: Suketu Upadhyay departs, Director—Leadership changesSource

Virax Biolabs Group Limited

At 5% or more1
Filings6
Latest filing2026-05-15

Virax Biolabs Group Limited has 6 Schedule 13D or 13G filings on record since 2025-10-29. 1 holder's latest filing reports 5% or more of ordinary shares, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
James Foster8.3%368,570SCHEDULE 13G/A, 2025-10-292025-03-31
Armistice Capital, LLC4.99%1,000,239SCHEDULE 13G/A, 2026-05-152026-03-31
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Armistice Capital, LLC01,000,23901,000,239SCHEDULE 13G/A, 2026-05-15
Steven Boyd01,000,23901,000,239SCHEDULE 13G/A, 2026-05-15

The latest filing identifies Virax Biolabs Group Limited by CUSIP G9495L125 and gives its principal executive office as BIOCITY GLASGOW, BO'NESS ROAD, NEWHOUSE, LANARKSHIRE (SCHEDULE 13G/A, 2026-05-15).

FiledHolderPercentFiling
2025-10-29James Foster24.9%SCHEDULE 13G
2025-10-29James Foster12.9%SCHEDULE 13G/A
2025-10-29James Foster7.3%SCHEDULE 13G/A
2025-10-29James Foster8.3%SCHEDULE 13G/A
2026-02-17Armistice Capital, LLC9.99%SCHEDULE 13G
2026-05-15Armistice Capital, LLC4.99%SCHEDULE 13G/A
DateRecordFigureOur pageSource
December 18, 2025Form D, private offering$5M soldForm D pageSource

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All 5%+ stakes

RSS